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Abstract 
 
Background/Aim. Due to the fact that there is a relatively 
small number of data related to systemic insulin 
abnormalities in the multiple sclerosis (MS), the main 
objective of our study was to determine whether a 
dysbalance of glucose and insulin metabolism exist in 
patients with natural course of MS. Our hypothesis was that 
the metabolic disorder that characterizes state of the insulin 
resistance (IR) and reduced insulin sensitivity (IS) in un-
treated patients with MS could play a role in disease pro-
gression and degree of functional disability. Methods. The 
study included 31 patients with relapsing-remitting (RR) MS 
and 14 healthy controls from the same geographic area 
matched by age, ethnicity and number of smokers. The 
glucose tolerance, IS, and IR were examined using an oral 
glucose tolerance test (OGTT) and using basal plasma 
glucose and insulin levels. The functional disability and 
disease progression were evaluated by the Expanded 
Disability Status Scale (EDSS) and Multiple Sclerosis 
Severity Score (MSSS). Results. The MS patients tolerated 
glucose equally well as the healthy controls. Basal concen-
trations of insulin were significantly higher in the MS group 
(p < 0.05), as well as insulin plasma level 30 min after oral 
glucose load (p < 0.01). The patients with MS had signifi-
cantly higher values of homeostasis model assessment in-
dexes of IR (HOMA-IR) (p = 0.027; p = 0.028). The per-
centage of IS (HOMA2 %S) and whole body IS index (ISI 
Matsuda) showed significantly lower values in the MS pa-
tients than in the controls (p = 0.005; p = 0.001). The insu-
linogenic index in the first 30 min of OGTT was signifi-
cantly higher in MS patients (p = 0.005). The measures of 
functional disability and MS progression did not correlate 
significantly with the investigated parameters of IR and IS 
indexes. Conclusion. This study demonstrates for the first 
time the existence of hyperinsulinemia, reduced insulin sen-
sitivity and normal glucose tolerance that indicate the initial 
phase of IR in the natural course of MS. Additional research 
is necessary in order to define the mechanisms of occur-
rence and the impact of IR on the complex pathophysi-
ological processes in MS. 
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Apstrakt 
 
Uvod/Cilj. S obzirom na činjenicu da ima relativno malo 
podataka koji se odnose na sistemske insulinske poremećaje 
u multiploj sklerozi (MS), osnovni  cilj našeg istraživanja bio 
je da utvrdimo da li kod obolelih od MS sa prirodnim 
tokom bolesti postoji disbalans u metabolizmu glukoze i 
insulina. Naša hipoteza je da metabolički poremećaj koji 
karakteriše stanje insulinske rezistencije (IR) i snižene 
insulinske senzitivnosti (IS)  kod nelečenih bolesnika sa MS 
može imati ulogu u progresiji bolesti i stepenu funcionalne 
onesposobljenosti. Metode. U studiju je bio uključen 31 
bolesnik sa dijagnozom relapsno remitentne (RR) MS i 14 
zdravih kontrolnih ispitanika sa istog geografskog područja 
usaglašenih po starosti, etničkoj pripadnosti, i zastupljenosti 
pušača. Tolerancija na glukozu, IS i IR procenjivani su na 
osnovu oralnog testa opretećenja glukozom (OGTT) i 
bazalnih vrednosti insulina i glukoze u serumu. Za kliničku 
procenu funkcionalne onesposobljenosti i progresije bolesti 
korišćeni su  Expanded Disability Status Scale (EDSS) i Multiple 
Sclerosis Severity Score (MSSS) skorovi. Rezultati. Bolesnici sa 
MS jednako su dobro tolerisali glukozu kao i kontrolna 
grupa zdravih. U grupi MS bolesnika bazalne koncentracije 
insulina u plazmi bile su statistički značajno veće (p < 0,05) 
kao i koncentarcije insulina 30 min nakog opterećenja 
glukozom (p < 0,01). Značajno veće vrednosti indeksa IR, i 
Homeostasis Model Assessment (HOMA-IR), imali su 
bolesnici sa MS nego zdrava kontrola. Pokazane su značajno 
niže vrednosti procenta IS (HOMA 2%S) i indeksa 
insulinske senzitivnosti celog tela (ISI Matsuda) kod MS 
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bolesnika nego kod kontrolne grupe (p = 0,005; p = 0,001). 
Insulinogeni indeks u prvih 30 min OGTT-a bio je značajno 
veći kod bolesnika sa MS. Ispitivani parametri IR i indeksi 
IS nisu pokazali značajnu povezanost sa stepenom 
funkcionalne onesposobljenosti i progresijom MS. 
Zaključak. U ovoj studiji  je po prvi put pokazano 
prisustvo hiperinsulinemije, smanjene IS uz očuvanu 
toleranciju na glukozu, što sve zajedno ukazuje na 
postojanje inicijalne faze sindroma IR kod bolesnika sa 
prirodnim tokom MS. Neophodna su dodatna istraživanja 
za definisanje mehanizama nastanka i uticaja IR na kom-
pleksne patofiziološke procese kod MS. 
 
Ključne reči: 
multipla skleroza; insulin, rezistencija; glukoza, test 
tolerancije; ankete i upitnici. 
 
Introduction 
Multiple sclerosis (MS) is a disease in which the 
inflammatory and degenerative processes coexist from the 
beginning with the different contribution in the pathogenesis, 
depending on the type and the course of the disease 1. 
In recent years there have been more and more evidence 
suggesting the importance of insulin in many physiological 
and pathophysiological functions in the central nervous 
system (CNS), exceeding its exclusive role as a peripheral 
hormone. The presence of the insulin receptor as well as the 
insulin-sensitive glucose transporter was identified in the 
brain of humans and animals 2. 
Insulin reactive areas of the brain are involved in the re-
gulation of peripheral metabolism, food intake, body weight, 
behavior control and cognition with primary effect on 
memory 3. Peripheral insulin crosses the blood-brain barrier by 
insulin-mediated transport mechanism. So far there is not eno-
ugh evidence which would confirm its local synthesis in the 
human brain 4, 5. On the other hand metabolic requirements of 
the brain are obtained by constant influx of glucose from blo-
od. It is considered that the cerebral glucose transport and me-
tabolism are meinly insulin independent and that the role of in-
sulin in brain glucose metabolism is controversial 6. 
The mechanisms by which insulin achieves its central 
effects are associated with insulin receptor expression, 
insulin signaling cascade, the neurotransmitter expression 
and modulation of several aspects of neuroinflammatory 
response 7, 8. 
Transport of insulin in CNS is compromised in conditions 
that are characterized by a reduced insulin sensitivity (IS) and 
insulin resistance (IR) in the periphery which is associated with 
the concept of brain insulin resistance 5, 9. 
Research in the past decade indicated a high degree of 
correlation between IR and peripheral hyperinsulinemia with 
neurodegenerative diseases such as Alzheimer's dementia, 
Huntington's disease and Parkinson's disease 10−12. 
A small number of recent studies conducted in different 
groups of MS patients suggest the presence of abnormalities 
in glucose and insulin metabolism. 
People with MS share equal  risk of developing diabetes 
mellitus type 2 compared to the general population, but are 
more prone to develop other autoimmune diseases, including 
diabetes mellitus type 1 7. Immunomodulatory therapy with 
interferon beta (IFNβ) further contributes to the risk of 
developing glucose dysregulation 13−15. 
Studies have indicated the prevalence of IR higher than 
40% in MS patients compared to the healthy subjects, ie 21% 16. 
Reduced IS and postprandial hyperinsulinemia was observed in 
the group of newly diagnosed MS patients 17. 
Due to the fact that there is a relatively small number of 
data related to IR in MS, especially in the group of patients 
with the natural course of the disease, the aim of this study 
was to examine glucose tolerance, insulin sensitivity and 
insulin resistance from an oral glucose tolerance test (OGTT) 
as well as from basal plasma glucose and insulin levels in the 
group of untreated patients with MS compared with healthy 
controls. The aim of this study was also to determine the 
relation between the level of functional disability expressed 
as Expanded Disability Status Scale (EDSS) and Multiple 
Sclerosis Severity Score (MSSS) with IR markers, in patients 
with MS. 
Our hypothesis is that the metabolic disorder that 
characterizes state of IR and reduced IS in patients with the 
natural course of MS could play a role in disease progression 
and degree of functional disability. 
Methods 
This clinical observational cross sectional study was con-
ducted in the Clinic of Neurology of Military Medical Academy 
in Belgrade. All procedures were conducted in accordance with 
regulations of Good Clinical Practice and were approved by the 
Ethics Committee of the Military Medical Academy in Belgra-
de. Before enroled in the study the patients had to sign a infor-
med consent for participation in the study. 
The patients suffering from MS were recruited from the 
register of patients of the Clinic of Neurology, Military Medi-
cal Academy in Belgrade. The study included 31 patients dia-
gnosed with relapsing-remitting MS (RRMS) according to the 
revised Mac Donald criteria from 2010, who did not receive 
treatment that modifies the natural course of the disease 18. 
All the RRMS patients were in a state of clinical remis-
sion and did not receive corticosteroid therapy three months 
before joining the study. 
The control group consisted of 14 patients selected 
from a population of healthy veterans from the same geo-
graphic area. 
A control group of healthy subjects and MS patients 
were matched by age, ethnicity and the number of smokers. 
The MS patients and healthy controls who had in their 
medical history any disease or medical condition that might 
be associated with brain pathology, diabetes mellitus, hepa-
tic, renal insufficiency, severe psychiatric or organic disease 
were excluded from the study. In addition, the patients, as 
well as the control group of healthy subjects were not taking 
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Table 1 
Main characteristics of controls and patients with multiple sclerosis 
Characteristics Controls n = 14 
Patients 
n = 31 p 
Age (years) 35.07 ± 6.41 35.20 ± 9.92 0.52 
BMI (kg/m2) 26.33 ± 2.54 23.70 ± 3.61 0.02 
Smoking, n (%) 7 (50.00) 11 (35.5) 0.36* 
HOMA-IR1, n (%) 0 (0.0) 6 (19.35) 0.07* 
HOMA-IR2, n (%) 4 (28.57) 12 (38.71) 0.51* 
Imp gluc tol, n (%) 5 (35.71) 12 (38.71) 0.85* 
EDSS   2.56 ± 1.09 N/A 
MSSS  4.48 ± 2.13 N/A 
any anti-inflammatory and hormone therapy or therapy 
which may affect the metabolic status. The subjects did not 
abuse alcohol or psychoactive substances nor were on the 
specific dietary regimen. 
Upon the arrival all the subjects were interviewed in 
order to collect demographic data, check inclusion and 
exclusion criteria and information about the history of MS. 
Physical examination, as well as anthropometric 
measurements (body weight, body height), were carried out. 
Body mass index (BMI) was obtained from the ratio of body 
weight (kg) and square of height (m2). In the patients with 
MS EDSS and MSSS were used for clinical evaluation of 
functional disability and disease progression. 
Blood samples were collected early in the morning after 
12 hours of fasting and venous cannula was placed. First off 
all, the basal values of glucose and insulin were determined 
in plasma and after that the subjects were asked to drink a 
solution containing 75 g of glucose in 250 mL water over 3 
minutes. Blood sampling for analysis of glycemia and 
insulinemia was then carried out 30 min and 120 min after 
the OGTT test. 
Plasma glucose concentrations were determined by 
enzymatic method using autoanalyzer (Dimesion RxL 
Siemens Health Care Diagnostics, Erlangen, Germany). 
Plasma insulin concentrations were determined by 
chemiluminescence immunoassay (Architect, Abbott 
Diagnostics Dicision, Wiesbaden, Germany). 
The parameters determined on the levels of fasting 
insulin and glucose were: homeostasis model assessment 
(HOMA), a widely accepted, surrogate, instrument for 
evaluation of IR in clinical and epidemiological studies 
which correlates well with the glucose clamp, and minimal 
model as direct and precise methods for the evaluation of 
IR and IS 19−21; [HOMA-IR index, the value obtained from 
the product of basal insulin levels (I0, mU/mL) and basal 
glycemia (G0, mmol/L) divided by the constant 22.5 22. 
Insulin resistance in the general population determined by 
the value of HOMA-IR ≥ 2.5]; updated HOMA 2 computer 
model also used for the assessment of IR (HOMA2-IR) and 
for determining IS (HOMA2-% S) and beta-cell function 
(HOMA2 -%β) from basal glucose and insulin values (this 
model output was calibrated so that normal β-cell function 
is 100%, and normal IR ≤ 1; http://www.dtu7.ox.ac.uk/ 
Homacalculator/download.php) 23.  
The parameters obtained from the OGTT test were: 
glucose tolerance, with impaired glucose tolerance (IGT) 
defined by values G0 (5.6−6.9 mmol/L) and/or glycemia in 2 
h test G120 (7.8−11.0 mmol/L) 19; insulinogenic index in the 
first 30 min of the test (IGI 30'), as a measure of the first 
phase of insulin response to glucose, is the parameter for es-
timation of β-cell activity, (the early phase of insulin 
secretion is calculated as the quotient of the incremental 
insulin and glucose concentrations in the first 30 minutes 21); 
indices of insulin sensitivity (Cederholm index (ISICED) is a 
measure of peripheral insulin sensitivity and Matsuda index 
(ISIMAT) is the index of insulin sensitivity of the whole body 
which implies a composite assessment of hepatic and muscle 
insulin sensitivity 24−26. 
Statistical analysis 
Differences in frequencies of categorical variables be-
tween the patients and the controls were calculated by χ2. Di-
stribution of continuous variables was tested by Kolmogo-
rov-Smirnov test with Lillieform's correction. The influence 
of categorical variable on the variability of continuous para-
meters was analyzed using ANOVA or Kruskal Waliss 
ANOVA. The correlations were investigated by Spearman's 
rank correlation test. The results are presented as mean ± 
standard deviation (SD). Statistical analysis was performed 
using Statistica Version 8, software package (StatSoft Inc, 
2008). In all tests, the differences with two-tailed alpha–
probability p < 0.05 were considered significant. 
Results 
The main characteristics of the analyzed groups, the pa-
tients with MS and the controls, are presented in Table 1. 
There were no significant difference in age, percentage of 
smokers, prevalence of glucose intolerance and insulin resis-
tance between the patients and the controls. The patients with 
Values are mean ± standard deviation for age, BMI, EDSS, MSSS; One-way ANOVA was used for comparison 
of continuous variables with normal distribution; *χ2-test was used for categorical variables; p values < 0.05 
were considered statistically significant; N/A- not applicable; BMI – body mass index; HOMA-IR – 
homeostasis model assessment index of insulin resistance; Imp gluc tol – impared glucose tolerance; EDSS – 
expanded disability status scale; MSSS – multiple sclerosis severity score. 
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Fig. 1 − Glucose and insulin plasma levels during OGTT in the patients with multiple sclerosis (MS) and the con-
trols; a) Glucose during 2 h OGTT at the time points 0, 30 and 120 minutes in the controls and the patients with 
MS; b) Insulin during 2 h OGTT at the time points 0, 30 and 120 minutes in controls and patients with MS.  
(controls, n = 14; patients, n = 31); All values are expressed as means, with their standard deviations represented by 
vertical bars; Kruskal-Wallis ANOVA,*p < 0.05, **p < 0.01. 
OGTT – oral glucose tolerance test. 
 
Table 2 
Parameters of insulin metabolism in controls and patients with multiple sclerosis (MS) 
Parameters Controls n=14 
Patients 
n=31 p 
HOMA-IR1  1.27 ± 0.67 1.91 ± 1.27 0.027* 
HOMA-IR2  0.74 ± 0.39 1.10 ± 0.71 0.028* 
HOMA2 %β 77.09 ± 31.63 102.65 ± 49.18 0.06* 
HOMA2 %S 9.26 ± 4.47 5.80 ± 2.22 0.005 
ISI MAT 166.69 ± 80.40 104.32 ± 40.05 0.001 
ISI CED 57.42 ± 22.27 51.12 ± 11.33 0.21 
AUC INS 59.5 ± 31.95 80.11 ± 33.81 0.023 
AUC GLUC 15.44 ± 2.83 15.42 ± 3.11 0.98 
0.005* 
MS had significantly lower BMI compared to the control 
subjects (p = 0.02). 
The values of glucose and insulin during 2 h OGTT, me-
asured at the time points of 0, 30 and 120 minutes, are presen-
ted in Figure 1. Plasma glucose values changed significantly 
during OGTT (increased and than decreased) in both, patients 
and controls (both p < 0.001, effect of test), but there was no 
difference between the patients and the controls (p > 0.05, ef-
fect of disease). On the other hand, the basal concentrations of 
insulin were significantly higher in the MS patients than in the 
controls (p < 0.05). Oral administration of glucose induced the 
significant increase of insulin after 30 minutes (p < 0.05, effect 
of test) as well as between patients with the MS and controls 
(p < 0.01, effect of disease) (Figure 1a and b). 
The parameters of insulin resistance, sensitivity and β cell 
function derived from fasting and OGTT measurements of glu-
cose and insulin are presented in Table 2. We detected the signi-
ficant difference in indexes of insulin resistance HOMA1-IR 
and HOMA2-IR between the patients and controls. The patients 
with MS had significantly higher values of HOMA, defined by 
both formulas for HOMA calculation. The percentage of insulin 
sensitivity, HOMA 2% S, was also significantly different, with 
lower values detected in the MS patients (Figure 2). The whole 
body insulin sensitivity index (ISI Matsuda) was significantly 
lower in the patients than in the controls, while peripheral index 
of insulin sensitivity (ISI Cederholm) was not. 
Also, the insulinogenic index in the first 30 min of 
OGTT (IGI 30′), the parameter that estimates β–cell function, 
was significantly higher in the patients with MS than in the 
controls (Figure 3). The insulin area under the curve (AUC) 
was significantly higher in the patients with MS, while the 
glucose AUC was comparable in both groups (Table 2). 
The measures of functional disability and MS progres-
sion (EDSS and MSSS) did not correlate significantly with 
the investigated parameters of insulin resistance (HOMA1-
IR, HOMA2-IR, INS0, INS30, INS120) as well as insulin 
IGI30′ (mU/mmoL) 6.30 ± 4.09 17.37 ± 22.65 
Values are presented as mean ± standard deviation; One-way ANOVA was 
used for comparison of continuous variables with normal distribution; 
*Kruskal-Wallis ANOVA test was used to compare values between controls 
and patients with MS for continuous variables that had skewed distribution; 
p values < 0.05 were considered statistically significant. 
HOMA-IR – homeostasis model assessment index of insulin resistance; ISI 
MAT – insulin sensitivity index; ISI CED – peripheral insulin sensitivity index; 
AUC − area under the curve; INS − insulin; GLUC – glucose; IGI30′ − 
insulinogenic index during the first 30 min. of oral glucose tolerance test. 
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Fig. 2 – HOMA-IR in the patients with multiple sclerosis (MS) and the controls: a) HOMA1-IR in the controls 
and the patients with MS; b) HOMA2-IR in the controls and the patients with MS  
(controls, n = 14; patients, n = 31).  
All values are expressed as means, with their standard deviations represented by vertical bars; Kruskal-Wallis 
ANOVA,*p < 0.05. HOMA-IR – Homeostasis model assessment-insulin resistance. 
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Fig. 3 − Insulinogenic index (IGI) during the first 30 min of OGTT (IGI 30′) in the controls and the patients with 
multiple sclerosis  (controls, n = 14; patients, n = 31); Kruskal-Wallis ANOVA, **p < 0.01). 
OGTT – oral glucose tolerance test.
sensitivity indexes (ISI MAT and ISI CED) or insulin response 
to glucose (IGI 30′). 
Discussion 
Our study indicate the presence of abnormal insulin and 
glucose metabolism in the patients with MS compared to the 
healthy control subjects matched in age, ethnicity and 
percentage of smokers. 
Insulin resistance means a reduced capacity of endo-
genous as well as exogenous insulin to stimulate tissue glu-
cose utilization. Decreased tissue reactivity to insulin starts 
maladaptive mechanisms with the aim to maintain optimal 
levels of glucose in blood and preserve homeostasis 7, 8. 
Pancreatic β-cells secrete more insulin and 
hyperinsulinemia temporarily maintains euglycemia. Inves-
tigation of IR progressed from its primary role in the pat-
hogenesis of diabetes and latterly it is the area of interest in 
a wide range of diseases. IR could represent a kind of 
common pathway through which negative environmental 
factors in interaction with genetic predisposition lead to 
metabolic, hemodynamic and inflammatory disorders. 
The main objective of our study was to demonstrate 
whether a dysbalance in the metabolism of glucose and 
insulin exist in patients with the natural course of MS, based 
on the parameters obtained from the OGTT. 
In the group of the patients with MS the prevalence of 
IR showed a trend towards significance compared to the 
healthy control subjects. Population studies in different 
geographic areas indicated the existence of large variability 
in cut-off HOMA-IR values that define IR 27, 28. 
Unfortunately, studies have not been conducted yet in our 
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population, so commonly accepted  cut-off value for IR > 2.5 
was used 22. 
Among this study subjects, who shared the same 
geographical and cultural characteristics and a similar 
genetic background, comparison of the HOMA-IR index 
values showed that the patients with MS, as a group, had 
significantly higher values compared to the healthy controls. 
Unlike the previous studies that examined the glucose 
and insulin metabolism in patients with MS, our study selec-
ted a group of RR MS patients with natural course of the di-
sease with the average disease duration of 6 years. The study 
of  Penesova et al. 17 included a group of untreated RR MS 
patients with a short duration of the disease, diagnosed 
immediately after the first episode of the symptoms, and a 
lower degree of functional disability where no statistically 
significant differences in the values of HOMA-IR indexes 
were found between the group of MS patients and the 
healthy subjects.  
Oliveira et al. 16 found a higher prevalence of IR based 
on HOMA-IR index in the group of MS patients with a 
similar duration of the disease as in our patients, but they 
included patients with RR MS and secundary progressive 
(SP) MS who were receiving immunomodulatory therapy. It 
has been shown that treatment with interferon induces IR and 
increases an incidence of diabetes mellitus 14, 29. 
A recent study has indicated that IFN β leads to IR by 
activation of signal transducer and activation of the transcrip-
tion (STAT1)/suppressor of cytokine signaling (SOCS). In-
creased expression of SOCS in liver and adipose tissue re-
sults in suppression of insulin signaling and reduction of 
glucose uptake and it also leads to suppression of insulin-
induced phosphorylation of insulin receptor substrate 
(IRS)-1 protein 14.  
Significantly higher values of HOMA-IR index in the 
group of our MS patients are consistent with the results of 
Oliveira et al. 16 although our patients were younger and 
were not treated with immunomodulatory therapy. Hence it 
can be suggested that insulin resistance is associated with 
MS independently on the therapy and a higher prevalence of 
IR in MS patients, 41% in their study compared to our group 
of subjects, 19.3%, could partly be explained by the effect of 
the therapy and older age.  
Wanting to explore the mechanism of glucose 
metabolism disorders in MS better, we opted for the use of 
OGTT by which we could gain an insight into glucose 
tolerance, insulin response to glucose stimulation as well as 
the sensitivity of peripheral tissues to insulin. 
Our results show that the MS patients tolerated glucose 
equally well as the healthy controls. There was no difference 
in individual glycemic time points, the form of curve and the 
area under the curve. However, the MS patients had 
significantly higher basal insulin concentrations and a signi-
ficant increase in insulin after oral administration of glucose. 
The values of the area under the curve for insulin were 
significantly higher in MS patients than in the healthy con-
trols. Increased insulin response suggests a reduced IS which 
confirms a significantly lower IS  index, HOMA 2%S, obtai-
ned in our work in the group of MS patients based on the 
calculations from basal levels of insulin and glucose. Moreo-
ver, we established a significantly lower insulin sensitivity 
index of the whole body ISIMAT, obtained on the basis of 
OGTT. These results are in agreement with the findings of 
Penesova et al. 17 who pointed out that the reduced IS is a 
probable cause for hyperinsulinemia in the newly diagnosed 
and untreated MS patients. The difference in the value of the 
peripheral insulin sensitivity index  ISICED  did not express a 
statistical significance between our patients and the healthy 
controls, in contrast to the results of Penesova et al. 17. A 
possible explanation is that the formula for calculating the 
ISICED contains value of the body weight included in the cal-
culation of BMI, which was significantly lower in the group 
of our patients. 
With the aim to get an indirect insight into the activity 
of pancreatic β-cells in the group of MS patients, we used a 
surrogate marker for evaluation of the first-phase insulin res-
ponse to glucose, IGI30', with a significantly higher value 
compared to the healthy control group. 
Low insulinogenic index proved to be a predictor of the 
development of DM type 2. A decrease in this parameter va-
lue accompanies the development of glucose intolerance 
when an impaired β-cell function does not provide a suffici-
ent increase in insulin secretion in relation to the 
requirements, which results in inadequate 
hyperinsulinemia 10. Considering that our patients tolerated 
glucose as well as the healthy subjects, an increased value of 
this index would speak in favor of preserved β-cell function 
compared to the increased demands dictated by reduced IS. 
Common findings for hyperinsulinemia, reduced IS  
and normal glucose tolerance could indicate the existence of 
the initial phase of IR  syndrome when there has still not oc-
curred a collapse of glucoregulation and when the pancreatic 
β-cells respond to IR with a significantly increased insulin 
secretion in a group of patients suffering from MS with the 
natural course of the disease and low levels of functional 
disability. 
The results of our study do not indicate any association 
between IR and IS with the level of functional disability and 
the disease progression. A low average EDSS score in our 
group of patients does not significantly limit their physical 
activity which annuls the potential impact of reduced 
physical activity in IR. On the other hand, given the low 
EDSS score and a shorter disease duration, 6 years in avera-
ge, it is possible that it would be necessary to check data on 
the absence of the connection of IR with the severity of func-
tional disability and the rate of disease progression, obtained 
in this study, in a group of patients with a longer duration of 
the disease or in longitudinal studies which track the tempo-
ral and causal link. 
Data from the previous studies indicate that IR accom-
panies other autoimmune diseases as well 30, 31. In patients 
with systemic lupus the connection with adipocytokines adi-
ponectin, leptin, and visfatin in pathophysiology of IR and 
their possible role were indicated, while in rheumatoid arthri-
tis (RA) the connection between seropositivity for rheumato-
id factor (RF) and anti-citrullinated antibodies to citrullinated 
protein antigens (ACPA) with IR was observed 31, 32. 
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In patients with RA an increased production of insulin 
was detected. The conclusion was that a common trigger of 
autoimmunity could contribute to the production of antibodi-
es directed to the insulin receptor, leading to IR, rather than 
the destruction of β cells 31. 
Inflammatory cytokines, tumor necrosis factor (TNF)-α, 
interleukin(IL)-6, IL-17, (IFN)–γ, which are elevated in pati-
ents with MS, are implicated in negative interactions at the 
level of insulin receptors, signaling pathways and regulation 
of the genes responsible for normal insulin activity, as well 
as at the level of mechanisms involved in the processes of 
reaction to insulin and peripheral glucose uptake. On the ot-
her hand, insulin abnormalities are associated with increased 
oxidative stress and inflammatory response 33, 34. 
The drugs from the thiazolidinedione group, agonists of 
peroxisome proliferator-activated receptor-γ (PPAR γ), 
which are widely used in the therapy of diabetes, because 
they lead to a decrease in the IR, expressed the ability to pre-
vent the occurrence of clinical signs and reduce the severity 
of the disease in the model of experimental autoimmune 
encephalomyelitis EAE. PPARγ receptor is expressed in the 
inflammatory infiltrates of the spinal cord in EAE 35. 
Considering that the activation of PPARγ has shown 
beneficial effects in the treatment of inflammatory diseases 
their potential benefit in the treatment of MS was sugges-
ted 36. These data suggest that chronic systemic inflammation 
and oxidative stress may have a prominent role in the deve-
lopment of IR and thus there is an assumption of a possible 
connection between IR with chronic inflammation in MS. 
Moreover, neurodegenerative diseases, particularly Al-
zheimer's dementia (AD), are associated with the existence 
of IR 7, 37, 38. A concept was recently introduced that consi-
ders AD a metabolic disease with impaired energy metabo-
lism and glucose utilization in the brain, based on the brain 
resistance to insulin and insulin-like growth factor 39. 
Cerebral IR is associated with peripheral IR and chronic 
hyperinsulinemia to which aging, obesity and dyslipidemia con-
tribute. On the other hand, it could be determined as soon as in 
the fetal period by maternal metabolic disorders which interact 
with the fetal brain as well as the genetic background 4, 7, 31.  
The influence of cerebral IR to neurodegeneration is carried out 
through a variety of mechanisms which include enhanced acti-
vation of kinases that pathologically phosphorylate the Tau pro-
tein, increase in the expression of amyloid-β precursor protein 
(AβPP) and the accumulation of amyloid, as well as an increase 
of oxidative stress, mitochondrial dysfunction and the activation 
of pro-inflammatory and pro-apoptotic cascades which represent 
a part of the pathogenetic process in MS 37, 38. 
A parallel degenerative process which takes place in the 
natural course of MS suggests a possible analogy in 
pathophysiological processes with other neurodegenerative 
diseases of the CNS, especially since MS is largely characte-
rized by the cognitive impairment 39−41. 
Limitation of the above research, a small number of 
subjects in the control group, is justified by the relatively 
difficult and invasive procedure that had to be carried out 
in the healthy subjects. All control subjects were males. 
This, however, did not affect the accuracy of the results gi-
ven the fact that statistical comparative analysis of all rele-
vant parameters of the assessment within the group of pati-
ents with MS did not indicate a significance in relation to 
gender 42. Considering a relatively small number of MS 
patients in this preliminary study, the results require further 
confirmation in a study with a larger number of drug naive 
patients with MS. 
Conclusion 
This study demonstrates for the first time the existence 
of IR in the natural course of RRMS, in patients not treated 
with any type of therapy that alters the natural course of the 
disease. Given the previously demonstrated presence of IR in 
the patients with MS who received immunomodulatory 
therapy, as well as a reduced insulin sensitivity in the newly 
diagnosed, untreated patients with MS, our opinion is that 
there is a dysregulation of glucose and insulin metabolism in 
MS and that additional research is necessary in order to defi-
ne the mechanisms of occurrence and the impact on the 
complex pathophysiological processes in the CNS of the pa-
tients with MS. 
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